$1.80
+0.06 (+3.45%)
Open$1.75
Previous Close$1.74
Day High$1.82
Day Low$1.74
52W High$5.50
52W Low$1.54
Volume—
Avg Volume548.5K
Market Cap75.72M
P/E Ratio—
EPS$-1.70
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+703.3% upside
Current
$1.80
$1.80
Target
$14.46
$14.46
$8.98
$14.46 avg
$17.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.60M | 19.31M | 20.88M |
| Net Income | -5,133,777 | -5,587,628 | -4,631,912 |
| Profit Margin | -27.6% | -28.9% | -22.2% |
| EBITDA | -5,451,350 | -5,303,939 | -6,015,367 |
| Free Cash Flow | -4,165,501 | -4,081,500 | -5,685,079 |
| Rev Growth | +22.8% | -8.3% | +12.1% |
| Debt/Equity | 0.56 | 0.49 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |